论文部分内容阅读
贝伦妥单抗-维多汀(brentuximab vedotin)是一种以CD30为靶点的新型肿瘤靶向治疗药物。2011年8月11日获FDA批准用于治疗霍奇金淋巴瘤和系统性间变性大细胞淋巴瘤(sALCL)。本文对其药理作用、药动学、药物相互作用、临床研究和安全性进行综述。
Berentuzumab-vetotin is a novel tumor-targeted drug targeting CD30. Approved by the FDA on August 11, 2011 for the treatment of Hodgkin’s Lymphoma and Systemic Anaplastic Large Cell Lymphoma (sALCL). This article reviews its pharmacology, pharmacokinetics, drug interactions, clinical studies and safety.